[DOI] [PMC free article] [PubMed] [Google Scholar] Yoshida S, Tamaoki M, Shikano T, et al
There are four GLP-1 FDA decisions to watch in 2026 Eli Lillys injectable Mounjaro, with a new indication to reduce the risk of major adverse cardiovascular events in patients with T2DM, is expected in mid-2026
Such drug-induced elevations compound the effects of systemic comorbidities, including hypertension, insulin resistance, and atherosclerosis, collectively impairing urate homeostasis through both enhanced production and reduced excretion
Enzymatic deficiency in primaquine-sensitive erythrocytes
[DOI] [PubMed] [Google Scholar] 63.Schwimmer J.B., Johnson J.S., Angeles J.E., Behling C., Belt P.H., Borecki I., Bross C., Durelle J., Goyal N.P., Hamilton G
One of the reasons retatrutide is drawing attention is because it brings a new direction in obesity care: The metabolic element is much more fluid and systemic with the addition of energy boost There is more focus on appetite regulation Medical supervision is still required It can help with diet due to appetite management One of the reasons energy matters is because an energy boost helps to further boost calorie burning
